Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer

NCT ID: NCT00422903

Last Updated: 2016-05-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 92 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-04-30
• Study Completion Date: 2011-04-30

Brief Summary

Evaluate the percentage of clinical objective responses (cOR) in patients with HER2 negative early breast cancer treated with pre operative (neoadjuvant)lapatinib and letrozole

Conditions

Neoplasms, Breast

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Letrozole plus placebo

Letrozole 2.5 mg administered orally fro 6 mos. plus placebo 1500 mg administered orally throughout the study until definitive surgery

Group Type: PLACEBO_COMPARATOR

letrozole

Intervention Type: DRUG

2.5 mg administered orally daily

placebo

Intervention Type: OTHER

1500 mg administered orally daily

Letrozole plus lapatininb

Letrozole 2.5 mg administered orally fro 6 mos. plus lapatinib 1500 mg administered orally throughout the study until definitive surgery

Group Type: EXPERIMENTAL

lapatinib

Intervention Type: DRUG

1500 mg administered orally daily

letrozole

Intervention Type: DRUG

2.5 mg administered orally daily

Interventions

lapatinib

1500 mg administered orally daily

Intervention Type: DRUG

letrozole

2.5 mg administered orally daily

Intervention Type: DRUG

placebo

1500 mg administered orally daily

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed infiltrating primary breast cancer of 2.0 cm or more in largest clinical diameter
• ER and/or PgR positive cancer (> 10% of positive cancer cell assessed by IHC)
• Postmenopausal status, defined by at least one of the following:

≥ 60 years of age < 60 years of age and amenorrheic for ≥ 12 months prior to day 1 < 60 years of age and amenorrheic for < 12 months prior to day, or without a uterus: luteinizing hormone (LH) and follicle stimulating hormone (FSH) values within postmenopausal range Prior bilateral oophorectomy Prior radiation castration with amenorrhea for at least 6 months

• HER2 negative tumors (IHC 0-2+, or FISH negative)
• Availability of tumor tissue suitable for biological and molecular examination before starting primary treatment
• Age over 18 years
• ECOG PS 0-1
• Normal organ and marrow function as defined below:

leukocytes > 3000/mL absolute neutrophil count > 1,500/mL platelets > 100,000/mL total bilirubin within normal institutional limits AST (SGOT)/ALT(SGPT)< 2.5 X institutional upper limit of normal Creatinine within normal institutional limits

• Cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or MUGA scan.
• Eligibility of patients receiving medications or substances known to affect, or with the potential to affect the activity or pharmacokinetics of lapatinib will be determined following review of their use by the Principal Investigator.

A list of medications and substances known or with the potential to interact with CYP450 isoenzymes is provided

• Ability to understand and the willingness to sign a written informed consent document.
• Ability to swallow and retain oral medication.

Exclusion Criteria

• Stage IIIB, IIIC, and inflammatory breast cancer
• Stage IV breast cancer
• Contraindication to the treatment with letrozole
• Prior treatment with chemotherapy, endocrine therapy or radiotherapy. Prior treatment with EGFR targeting therapies
• Treatment with any other investigational agents, or with all herbal (alternative) medicines
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
• Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• HIV-positive patients receiving combination anti-retroviral therapy
• GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)
• Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors (See section 3.7.4.2 Other concomitant treatments)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Brindisi, Apulia, Italy

GSK Investigational Site

Carpi (MO), Emilia-Romagna, Italy

GSK Investigational Site

Forlì, Emilia-Romagna, Italy

GSK Investigational Site

Modena, Emilia-Romagna, Italy

GSK Investigational Site

Piacenza, Emilia-Romagna, Italy

GSK Investigational Site

Rimini, Emilia-Romagna, Italy

GSK Investigational Site

Treviglio (BG), Lombardy, Italy

GSK Investigational Site

Pisa, Tuscany, Italy

GSK Investigational Site

Chieti, , Italy

GSK Investigational Site

Cremona, , Italy

GSK Investigational Site

Perugia, , Italy

GSK Investigational Site

Reggio Emilia, , Italy

GSK Investigational Site

Varese, , Italy

GSK Investigational Site

Badalona, , Spain

Countries

Italy; Spain

Other Identifiers

EGF107692

Identifier Type: -

Identifier Source: org_study_id